First‑Line SSRI Recommendations for Geriatric Depression

Preferred First‑Line SSRIs

• The American Family Physician guidelines recommend sertraline, citalopram, and escitalopram as the preferred first‑line SSRIs for adults ≥ 65 years with major depressive disorder, based on their favorable efficacy‑tolerability‑safety profile. 1
• Recommended starting and maximum doses (per American Family Physician) are:

SSRIs to Avoid in Older Adults

• Paroxetine should be avoided because of its higher anticholinergic burden, which increases the risk of confusion, falls, and cognitive impairment in older patients. [1][5]
• Fluoxetine should be avoided due to its very long half‑life (exceeding one week with active metabolites), leading to prolonged side effects, delayed resolution of drug interactions, and a greater risk of agitation and overstimulation. [1][5]

Dosing Strategy – “Start Low, Go Slow”

• Initiate therapy at approximately 50 % of the standard adult starting dose for SSRIs in older adults. [6][5]
• Older adults have a significantly greater risk of adverse drug reactions; therefore, dose titration should be gradual and guided by clinical response and tolerability. 6

Treatment Duration and Maintenance

• After achieving remission of a first depressive episode, continue antidepressant therapy for at least 4–12 months. [1][2]3
• For patients with two prior episodes, consider maintenance therapy for 1–3 years; for those with three or more episodes, consider indefinite maintenance. 6

Management of Common Adverse Effects

• Approximately 63 % of older patients experience at least one adverse effect (most commonly nausea); these effects usually resolve within 2–3 weeks, and patients should be counseled to maintain therapy during this period. [1][7]
• Paroxetine should be avoided in individuals with existing cognitive impairment, urinary retention, constipation, or high fall risk because of its anticholinergic properties. [1][5]

Alternative Antidepressant Options (When SSRIs Are Contraindicated or Ineffective)

• Mirtazapine, venlafaxine, and bupropion are acceptable alternatives for geriatric depression. [1][2]3
• Venlafaxine is associated with a slightly higher discontinuation rate due to nausea and vomiting compared with SSRIs. [1][2]
• Mirtazapine commonly causes sedation and weight gain, which can be advantageous for patients with insomnia and poor appetite. 4

Efficacy Expectations for SSRIs in Older Adults

• All SSRIs demonstrate modest superiority over placebo, with a number needed to treat of 7–8 to achieve remission. [1][2]7
• Antidepressant efficacy is greatest in patients with severe depression, with reduced benefit in mild‑to‑moderate cases. [1][2]5